VERTEX PHARMACEUTICALS INC / MA Interest Expense Nonoperating
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Interest Expense Nonoperating of $13.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-02-13
- VERTEX PHARMACEUTICALS INC / MA interest expense nonoperating for the quarter ending 2025-12-31 was $3.30M, a 17.86% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA interest expense nonoperating for the quarter ending 2025-09-30 was $3.30M, a 56.00% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA interest expense nonoperating for the quarter ending 2025-06-30 was $3.70M, a 62.63% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA interest expense nonoperating for the quarter ending 2025-03-31 was $3.00M, a 71.15% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA interest expense nonoperating for fiscal 2025 was $13.30M, a 56.54% decline from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA interest expense nonoperating for fiscal 2024 was $30.60M, a 30.61% decline from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA interest expense nonoperating for fiscal 2023 was $44.10M, a 19.53% decline from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA interest expense nonoperating for fiscal 2022 was $54.80M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2025-12-31 | $3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $6.60M derived: sum of 2 quarters · filed 2026-02-13 | $10.30M derived: sum of 3 quarters · filed 2026-02-13 | $13.30M 10-K · filed 2026-02-13 |
| 2025-09-30 | $3.30M 10-Q · filed 2025-11-04 | $7.00M derived: sum of 2 quarters · filed 2025-11-04 | $10.00M 10-Q · filed 2025-11-04 | $12.80M derived: sum of 4 quarters · filed 2026-02-13 |
| 2025-06-30 | $3.70M 10-Q · filed 2025-08-05 | $6.70M 10-Q · filed 2025-08-05 | $9.50M derived: sum of 3 quarters · filed 2026-02-13 | $17.00M derived: sum of 4 quarters · filed 2026-02-13 |
| 2025-03-31 | $3.00M 10-Q · filed 2025-05-06 | $5.80M derived: sum of 2 quarters · filed 2026-02-13 | $13.30M derived: sum of 3 quarters · filed 2026-02-13 | $23.20M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $10.30M derived: sum of 2 quarters · filed 2026-02-13 | $20.20M derived: sum of 3 quarters · filed 2026-02-13 | $30.60M 10-K · filed 2026-02-13 |
| 2024-09-30 | $7.50M 10-Q · filed 2025-11-04 | $17.40M derived: sum of 2 quarters · filed 2025-11-04 | $27.80M 10-Q · filed 2025-11-04 | $38.40M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-06-30 | $9.90M 10-Q · filed 2025-08-05 | $20.30M 10-Q · filed 2025-08-05 | $30.90M derived: sum of 3 quarters · filed 2026-02-13 | $41.80M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-03-31 | $10.40M 10-Q · filed 2025-05-06 | $21.00M derived: sum of 2 quarters · filed 2026-02-13 | $31.90M derived: sum of 3 quarters · filed 2026-02-13 | $43.10M derived: sum of 4 quarters · filed 2026-02-13 |
| 2023-12-31 | $10.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $21.50M derived: sum of 2 quarters · filed 2026-02-13 | $32.70M derived: sum of 3 quarters · filed 2026-02-13 | $44.10M 10-K · filed 2026-02-13 |
| 2023-09-30 | $10.90M 10-Q · filed 2024-11-05 | $22.10M derived: sum of 2 quarters · filed 2024-11-05 | $33.50M 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $11.20M 10-Q · filed 2024-08-02 | $22.60M 10-Q · filed 2024-08-02 | ||
| 2022-12-31 | $54.80M 10-K · filed 2025-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |